Merck and Arvinas are entered into an R&D deal to a novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
Financial details are not disclosed.
View the full release here.
Merck and Arvinas are entered into an R&D deal to a novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics.
Financial details are not disclosed.
View the full release here.